<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057395</url>
  </required_header>
  <id_info>
    <org_study_id>C-726-04</org_study_id>
    <nct_id>NCT00057395</nct_id>
  </id_info>
  <brief_title>A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies</brief_title>
  <official_title>A Phase I/II Study of Aroplatin™ in Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aronex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aronex Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      To determine the rate of response and the duration of the response following therapy with
      Aroplatinin patients with advanced solid malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

        -  Determine response rate (RR; complete and partial response [CR, PR]) and duration after
           therapy with Aroplatin™ in patients with advanced solid malignancies.

      Secondary Objective:

        -  Determine the safety and tolerability of Aroplatin
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aroplatin (Liposomal NDDP, L-NDDP)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced solid malignancies;

          -  Amenable to therapy with DACH platinum agents;

          -  Measurable disease (RECIST criteria);

          -  ECOG performance score of 0-2;

          -  Adequate hematopoietic, liver and renal function;

          -  Adequate cardiac function (maximum of class II, NYHA);

          -  Women of childbearing potential must have a negative urine or serum pregnancy test;

          -  Signed written informed consent;

          -  Subjects must be willing to be followed during the course of treatment/observation and
             follow-up.

        Exclusion Criteria:

          -  No other active malignancies;

          -  No prior therapy with oxaliplatin;

          -  No known brain metastases;

          -  Active, uncontrolled infection or other serious medical illnesses;

          -  Not using or have used any investigational therapy during four weeks before start of
             protocol treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2003</study_first_submitted>
  <study_first_submitted_qc>April 1, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2003</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Esophageal Neoplasms</keyword>
  <keyword>Esophagus Neoplasm</keyword>
  <keyword>Esophagus Cancer</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Esophageal Tumors</keyword>
  <keyword>Esophagus Tumors</keyword>
  <keyword>Neoplasms, Esophageal</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>Hepatoma</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Colorectal Carcinoma</keyword>
  <keyword>Colorectal Tumor</keyword>
  <keyword>Neoplasms, Colorectal</keyword>
  <keyword>Ovarian Neoplasms</keyword>
  <keyword>Ovary Neoplasms</keyword>
  <keyword>Ovary Cancer</keyword>
  <keyword>Ovary Carcinoma</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Ovarian Carcinoma</keyword>
  <keyword>Neoplasms, Ovarian</keyword>
  <keyword>Pancreatic Neoplasms</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Pancreas Neoplasms</keyword>
  <keyword>Pancreas Cancer</keyword>
  <keyword>Neoplasms, Pancreatic</keyword>
  <keyword>Neoplasms, Pancreas</keyword>
  <keyword>and other solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

